Back To The Future: Gilead Signs Up Four Indian Companies To License Late-stage AIDS Therapies
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a strategic step looking to protect intellectual property rights while ensuring access to affordable life-saving medicines in developing nations, anti-HIV drugs specialist Gilead Sciences Inc. struck licensing deals July 12 with four India-based drug manufacturers - Hetero Drugs Ltd., Ranbaxy Laboratories Ltd., Strides Arcolab Ltd., and Matrix Laboratories Ltd. - for three Gilead drugs that are in late-stage clinical development
You may also be interested in...
Relevant Pipeline Brings Gilead Closer to Direct Indian Presence
Long after it has established business links with Indian drug makers, Gilead Sciences is looking to set up its own India office. All these years, the US firm has stopped shy of a direct presence but the growing relevance of its drug pipeline to the local population now makes this a strategic imperative, say industry insiders.
Gilead May Face Uphill Task With Sovaldi Despite Voluntary License Plan With Indian Generic Firms
Gilead may face unexpected speed bumps related to Sovaldi patents in India as it tries to extend the reach of its breakthrough HCV treatment via a combination of strategies, including voluntary licenses with Indian generics firms.
Asia Spotlight: Gilead Won’t Give Up Easily On Viread Patent Battle In China
China’s State Intellectual Property Office announced the invalidation of a patent for Viread, which is manufactured by Gilead and distributed by GSK in China. However, Gilead still holds several patents to protect the drug in China.